Calithera Biosciences, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Stephanie Wong
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 343 Oyster Point Boulevard South San Francisco CA United States of America 94080
- IPO Date
- Oct 2, 2014
- CIK
- 0001496671
- Website
- calithera.com
- Similar Companies
- Business
- Calithera Biosciences, Inc. (CALA) operates as a shell company under a plan of complete liquidation and winding down of operations approved by shareholders in January 2023; the firm previously functioned as a clinical-stage biopharmaceutical enterprise focused on developing small-molecule drugs targeting tumor metabolism and tumor immunology for cancer treatment. Core products and services encompassed glutaminase inhibitor telaglenastat (CB-839) for advanced renal cell carcinoma and other solid tumors; arginase inhibitor CB-280 for solid tumors; CD73 inhibitor prexigebersen (formerly INCB001158) for relapsed or refractory cancers; and additional candidates like mivavotinib and sapanisertib (which received FDA Fast Track designation for sqNSCLC with NRF2 mutations), all employing a biomarker-driven precision oncology approach for patients with aggressive hematologic and solid malignancies. The company, founded in 2010 and headquartered in South San Francisco, California, conducted U.S.-based research and development with past collaborations including Incyte, Pfizer, and Antengene, now under review amid bankruptcy proceedings.
Calithera Biosciences (NASDAQ:CALA) Shares Pass Above Fifty Day Moving Average – What’s Next?
Merck KGaA (OTCMKTS:MKGAF) & Calithera Biosciences (NASDAQ:CALA) Head to Head Contrast
Calithera Biosciences (NASDAQ:CALA) Stock Passes Above Fifty Day Moving Average – Time to Sell?
Marriott International Announces Changes to its Continent Leadership and a Strategic Realignment Across Key Regions
Calithera Biosciences, Inc. (CALA) Q3 2022 Earnings Call Transcript
Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
Calithera's stock is up 14% after announcing Fast Track designation for lung-cancer drug candidate
3 Penny Stocks With Surprisingly Superior Fundamentals
Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q2 2022 Results - Earnings Call Transcript
What Is a Reverse Stock Split and How Does It Work?
What is a Reverse Stock Split and How Does it Work?
Calithera to Present at the H.C. Wainwright Global Investment Conference
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q1 2022 Results - Earnings Call Transcript
Calithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
Best Penny Stocks to Buy Under $1 Now? 3 to Watch in May
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2021 Results - Earnings Call Transcript
Calithera Biosciences Raises $10M Via Equity Issued At 10% Discount
3 Hot Meme Penny Stocks to Watch Under $3 Right Now
Calithera Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 31, 2022